Novo Nordisk Announces Major Restructuring Amidst Competitive Challenges
In a decisive move to refocus its strategy, Novo Nordisk has announced a substantial restructuring plan intended to better position the company in the highly competitive landscape of chronic disease treatments, particularly in obesity and diabetes, reports 24brussels.
This announcement marks one of the first initiatives by newly appointed CEO, Doustdar, who took over the reins from Lars Fruergaard Jørgensen earlier this year. Under Jørgensen’s leadership, Novo Nordisk emerged as the most valuable company in Europe over the past eight years. However, the company has experienced significant setbacks recently, with its share price declining due to intensified competition in the weight-loss drug sector, particularly from Eli Lilly’s Mounjaro, coupled with disappointing results from trials for its next-generation therapies.
“Our markets are evolving, particularly in obesity, as it has become more competitive and consumer-driven. Our company must evolve as well,” Doustdar stated, emphasizing the need for adaptation in response to market dynamics.
As part of the restructuring, the company estimates one-off costs amounting to 8 billion Danish krone (€1.07 billion). This decision underscores the urgency for Novo Nordisk to streamline operations and redirect resources towards areas that promise sustainable growth and innovation.
Additionally, the firm has adjusted its full-year operating profit growth expectations to a range of 4 percent to 10 percent, a notable decrease from the previous forecast of 10 percent to 16 percent issued in August. This revision reflects the challenges the company faces in fulfilling its ambitious growth targets amid a shifting industry paradigm.